Becton, Dickinson and Company (NYSE:BDX – Get Free Report) announced that its board has authorized a share buyback program on Tuesday, January 28th, RTT News reports. The company plans to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.
Becton, Dickinson and Company Trading Up 0.4 %
NYSE:BDX opened at $249.75 on Wednesday. The business’s 50-day simple moving average is $228.56 and its 200-day simple moving average is $233.31. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $250.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The stock has a market capitalization of $72.43 billion, a PE ratio of 42.05, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the company posted $3.42 earnings per share. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. Sell-side analysts expect that Becton, Dickinson and Company will post 14.42 earnings per share for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the stock. Piper Sandler increased their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $283.00.
Check Out Our Latest Stock Report on BDX
Insiders Place Their Bets
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of the stock in a transaction on Friday, January 17th. The stock was sold at an average price of $236.51, for a total transaction of $141,196.47. Following the transaction, the executive vice president now owns 5,544 shares in the company, valued at $1,311,211.44. This trade represents a 9.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock valued at $2,210,716 in the last 90 days. 0.36% of the stock is currently owned by insiders.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Expert Stock Trading Psychology Tips
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Health Care Stocks Explained: Why You Might Want to Invest
- What Does the Future Hold for Eli Lilly?
- Why is the Ex-Dividend Date Significant to Investors?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.